证券代码：002326 证券简称：永太科技 公告编号：2025-006 浙江永太科技股份有限公司 关于公司部分银行账户解除冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、对公司的影响及风险提示 本次公司部分资金解除冻结，对公司的生产经营管理有积极影响，有利于公 司的资金划转和使用。截至本公告披露日，本次部分资金解除冻结后，公司募集 资金专户剩余被冻结金额为 102,214,612.11 元，占公司募集资金净额的 20.54%， 占公司最近一期经审计净资产的 3.23%，占公司最近一期经审计货币资金的 9.22%，占比相对较小，因此不会对公司募集资金投资项目产生重大不利影响。 公司将尽快消除资金被冻结的风险，使剩余被冻结银行账户尽快恢复正常。 公司将持续关注有关事项的后续进展并及时按照相关法律法规的要求履行信息 披露义务。敬请广大投资者注意投资风险。 特此公告。 浙江永太科技股份有限公司 董 事 会 2025 年 1 月 25 日 浙江永太科技股份有限公司（以下简称"公司"）与肥东国轩新材料有限公 司因买卖合同纠纷事宜，双方各自向法院提起诉讼，并 ...

证券代码：002326 证券简称：永太科技 公告编号：2025-005 浙江永太科技股份有限公司 关于公司诉讼事项的进展及部分银行账户解除冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江永太科技股份有限公司（以下简称"公司"）与肥东国轩新材料有限公 司因买卖合同纠纷事宜，双方各自向法院提起诉讼，并实施了财产保全措施，具 体内容详见公司于 2023 年 12 月 19 日披露的《关于公司诉讼事项的公告》（公 告编号：2023-082）、《关于公司部分银行账户被冻结的公告》（公告编号： 2023-083）及 2024 年 1 月 9 日披露的《关于公司收到民事起诉状的公告》（公 告编号：2024-001）。 上述案件一审均已开庭审理，公司已收到安徽省合肥市中级人民法院出具的 《民事判决书》（2023）皖 01 民初 1693 号及（2024）皖 01 民初 570 号，具体 内容详见公司于 2024 年 12 月 31 日披露的《关于诉讼事项的进展公告》（公告 编号：2024-080）。一审判决后，双方均未上诉并达成了和解，在一审判决的基 础上对款 ...

Financial Performance - The company expects a net profit attributable to shareholders to range from a loss of 36,000 to 48,000 million yuan, compared to a loss of 61,976.14 million yuan in the same period last year, indicating an improvement[3]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 33,000 to 45,000 million yuan, down from a loss of 69,636.16 million yuan year-on-year, reflecting a reduction in losses by approximately 24,600 to 36,600 million yuan[3][5]. - Operating revenue is anticipated to be between 400,000 and 500,000 million yuan, slightly down from 412,804.08 million yuan in the previous year[3]. Segment Performance - The lithium battery materials segment has shown improved performance, with significant reductions in losses due to stabilized market prices and enhanced operational efficiency[6]. - The agricultural protection and trading segments have also seen growth in sales scale and gross profit, driven by recovering market demand and successful product launches[6]. Challenges and Strategies - The company has not yet achieved profitability, primarily due to low market prices for lithium materials and declining prices for certain pharmaceutical products[6]. - The company plans to continue expanding market efforts and improving cost control to enhance profitability and operational conditions[6].

证券代码：002326 证券简称：永太科技 公告编号：2024-080 浙江永太科技股份有限公司 关于诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：案件一、案件二均已作出一审判决； 2、公司所处的当事人地位：案件一中公司为被告；案件二中公司为原告； 案件一、案件二为同一事项相关联的两个案件； 3、涉案的金额：案件一起诉初始金额为人民币 202,539,167 元；案件二起诉 初始金额为人民币 311,183,184.51 元； 4、对公司损益产生的影响: 本次诉讼判决均为一审判决，目前尚未生效， 当事人有权在规定期限内提起上诉，案件最终判决结果、执行情况等存在不确定 性。公司将依据会计准则的要求和案件进展的实际情况进行相应的会计处理，该 诉讼事项对公司本期利润或期后利润的影响以法院生效判决的实际发生金额为 准。 浙江永太科技股份有限公司（以下简称"公司""浙江永太公司"）于近日 收到安徽省合肥市中级人民法院送达的（2023）皖 01 民初 1693 号及（2024）皖 01 民初 570 号《民事判 ...

证券代码：002326 证券简称：永太科技 公告编号：2024-079 浙江永太科技股份有限公司 单位：万元 | 被担保方 | 经审议担保 | 本次担保前 | 本次使用 | 本次担保后 | 本次担保后 | | --- | --- | --- | --- | --- | --- | | | 额度 | 担保余额 | 担保额度 | 担保余额 | 可用担保额度 | | | | 二、 被担保人基本情况 被担保人名称：内蒙古永太化学有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江永太科技股份有限公司（以下简称"公司"）经 2024 年 5 月 16 日召开 的 2023 年年度股东大会审议通过，同意公司对纳入合并报表范围内的部分子公 司提供累计总额不超过人民币 355,000 万元的担保，该担保额度可循环使用，即 为其向国内各类银行及其他机构的融资（包括但不限于人民币/外币贷款、银行承 兑、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁等）提供连带责 任保证。其中对资产负债率未超过 70%的部分子公司提供担 ...

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang. It is a global leader in fluorine fine chemicals manufacturing, covering both inorganic and organic fluorochemical industries [2]. - The company has multiple production bases in Zhejiang, Inner Mongolia, Fujian, and Guangdong, with sufficient existing, under-construction, and planned capacities to support future core business growth [2]. Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of CNY 333,876.45 million, representing a 7.30% increase, primarily driven by the recovery in the pesticide industry [3]. - The overall gross margin improved from 15.30% in the same period last year to 17.62% this year, while management, sales, and R&D expenses decreased, resulting in a net profit loss of CNY 10,620.40 million, a reduction of CNY 7,830.42 million year-on-year [3]. Lithium Battery Materials Segment - The lithium battery materials segment has established a vertically integrated supply chain from lithium salt raw materials to electrolytes. Current production capacities include: - Solid lithium hexafluorophosphate: approximately 18,000 tons/year - Liquid lithium bis(fluorosulfonyl)imide: 67,000 tons/year in trial production [4]. - Additives: VC product at 5,000 tons/year and FEC product at 3,000 tons/year [3]. - Electrolytes: 150,000 tons/year [3]. Pharmaceutical Segment - The pharmaceutical segment has developed a vertically integrated supply chain covering cardiovascular, diabetes, central nervous system, anti-infection, and antiviral fields. Several products have received drug registration certificates from the National Medical Products Administration [4]. - The company plans to leverage core technologies to deepen development in various therapeutic areas, focusing on integrated layouts of intermediates, raw materials, and formulations [4]. Market Outlook and Strategy - The company is optimistic about the future of the lithium battery materials segment, driven by the increasing market penetration of electric vehicles. It aims to enhance market competitiveness through technological iterations and process improvements [5]. - The company is actively capturing market share in the electrolyte sector, with increasing shipment volumes. It plans to maintain competitiveness through economies of scale and optimized production processes [4]. - The demand for lithium bis(fluorosulfonyl)imide is expected to grow due to its superior properties, with production capacity currently at 67,000 tons/year [4]. Conclusion - The investor relations activity did not involve any undisclosed significant information, and the company remains focused on adjusting production and sales strategies based on market developments to enhance core competitiveness [5].

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province, specializing in fluorine fine chemicals [2] - The company operates across the inorganic and organic fluorochemical industries, covering new materials, pharmaceuticals, plant protection, and trade [2] Performance Overview - In Q1 2024, the company achieved a revenue of CNY 333,876.45 million, a year-on-year increase of 7.30% [3] - The gross profit margin improved from 15.30% in the same period last year to 17.62% this year, while net profit after deducting non-recurring items was -CNY 10,620.40 million, a decrease in loss of CNY 7,830.42 million [3] Lithium Battery Materials Segment - The lithium battery materials segment has established a vertically integrated supply chain, with production capacities as follows: - Solid lithium hexafluorophosphate: approximately 18,000 tons/year - Liquid lithium bis(fluorosulfonyl)imide: 67,000 tons/year in trial production [3] - Additives: VC product at 5,000 tons/year and FEC product at 3,000 tons/year [3] - Electrolyte: 150,000 tons/year [3] - Future strategies include enhancing R&D and product layout to meet customer needs across the supply chain [3] Pharmaceutical Segment - The pharmaceutical segment has developed a vertically integrated supply chain covering cardiovascular, diabetes, central nervous system, anti-infection, and antiviral fields [4] - Several pharmaceutical products have received approval from the National Medical Products Administration, and the subsidiary Yongtai Pharmaceutical has passed FDA inspections [4] Trade Business - In H1 2024, trade business revenue accounted for 37.16% of total revenue, primarily driven by Shanghai Nonghui, which manages over 1,000 pesticide registrations overseas [5] - The proportion of trade business may decrease as the company focuses on lithium, pharmaceuticals, and plant protection as core businesses [5] Profitability Analysis - In H1 2024, the gross margin for pharmaceutical products was 44.17%, while the lithium battery materials segment saw a gross margin of 6.03%, an increase of 14.51 percentage points year-on-year [5] - The plant protection segment's gross margin was 33.68%, up 4.89 percentage points year-on-year, but faced pressure in Q3 due to price declines [5] Future Outlook - The company aims to enhance its market competitiveness in the lithium materials segment despite current profit pressures, with increasing shipment volumes [6] - The pharmaceutical segment will focus on high-value-added products and expand domestic market presence [6] - The plant protection segment will strengthen collaboration with the trade segment to optimize production and sales coordination [6]

证券代码：002326 证券简称：永太科技 公告编号：2024-078 浙江永太科技股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江永太科技股份有限公司（以下简称"公司"）经 2024 年 5 月 16 日召开 的 2023 年年度股东大会审议通过，同意公司对纳入合并报表范围内的部分子公 司提供累计总额不超过人民币 355,000 万元的担保，该担保额度可循环使用，即 为其向国内各类银行及其他机构的融资（包括但不限于人民币/外币贷款、银行承 兑、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁等）提供连带责 任保证。其中对资产负债率未超过 70%的部分子公司提供担保额度不超过 155,000 万元，对资产负债率超过 70%的部分子公司提供担保额度不超过 200,000 万元。担保额度可在子公司之间进行调剂，但在调剂发生时，资产负债率超过 70% 的担保对象，仅能从资产负债率超过 70%的担保对象处获得担保额度。担保方式 包括但不限于保证、抵押、质押，具体担保金额及保证期间按具体合同约定执行。 ...

证券代码：002326 证券简称：永太科技 公告编号：2024-077 浙江永太科技股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江永太科技股份有限公司（以下简称"公司"）经 2024 年 5 月 16 日召开 的 2023 年年度股东大会审议通过，同意公司对纳入合并报表范围内的部分子公 司提供累计总额不超过人民币 355,000 万元的担保，该担保额度可循环使用，即 为其向国内各类银行及其他机构的融资（包括但不限于人民币/外币贷款、银行承 兑、信用证开证、进出口押汇、打包贷款、银行保函、融资租赁等）提供连带责 任保证。其中对资产负债率未超过 70%的部分子公司提供担保额度不超过 155,000 万元，对资产负债率超过 70%的部分子公司提供担保额度不超过 200,000 万元。担保额度可在子公司之间进行调剂，但在调剂发生时，资产负债率超过 70% 的担保对象，仅能从资产负债率超过 70%的担保对象处获得担保额度。担保方式 包括但不限于保证、抵押、质押，具体担保金额及保证期间按具体合同约定执行。 ...

证券代码：002326 证券简称：永太科技 公告编号：2024-076 浙江永太科技股份有限公司 | 股东 名称 | 是否为第一 大股东及一 | 本次质押数 量（万股） | 占其所持股 份比例(%) | 占公司总股 本比例(%) | 是否为 限售股 | 是否为补 充质押 | 质押 开始日 | 质押 到期日 | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 致行动人 | | | | | | | | | | | | | | | | | | | 至质权人申 | 上海海通证 | 个人 | | 王莺妹 | 是 | 2,201.00 | 15.26 | 2.38 | 否 | 否 | 2024-10-29 | 请解除质押 | 券资产管理 | 资金 | | | | | | | | | | 之日止 | 有限公司 | 需求 | 二、股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 已质押股份情况 | ...